276.1 USD
+0.42 (+0.15%)
Taking everything into account, CME scores 5 out of 10 in our fundamental rating. CME was compared to 237 industry peers in the Capital Markets industry. CME has an excellent profitability rating, but there are some minor concerns on its financial health. CME is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CME was profitable.
In the past year CME had a positive cash flow from operations.
In the past 5 years CME has always been profitable.
Each year in the past 5 years CME had a positive operating cash flow.
1.2 Ratios
The Return On Assets of CME (1.99%) is comparable to the rest of the industry.
CME has a Return On Equity of 13.18%. This is in the better half of the industry: CME outperforms 71.73% of its industry peers.
CME has a Return On Invested Capital of 18.72%. This is amongst the best in the industry. CME outperforms 95.78% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CME is significantly above the industry average of 6.96%.
The 3 year average ROIC (15.81%) for CME is below the current ROIC(18.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROIC | 18.72% |
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
1.3 Margins
The Profit Margin of CME (32.91%) is better than 78.06% of its industry peers.
In the last couple of years the Profit Margin of CME has declined.
The Operating Margin of CME (80.16%) is better than 98.73% of its industry peers.
In the last couple of years the Operating Margin of CME has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A |
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CME has about the same amout of shares outstanding than it did 1 year ago.
CME has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CME has an improved debt to assets ratio.
2.2 Solvency
CME has a debt to FCF ratio of 0.84. This is a very positive value and a sign of high solvency as it would only need 0.84 years to pay back of all of its debts.
The Debt to FCF ratio of CME (0.84) is better than 89.87% of its industry peers.
CME has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.12, CME is doing good in the industry, outperforming 77.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.84 | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CME has a Current Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
CME has a Current ratio (1.02) which is in line with its industry peers.
A Quick Ratio of 1.02 indicates that CME should not have too much problems paying its short term obligations.
CME's Quick ratio of 1.02 is in line compared to the rest of the industry. CME outperforms 48.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
CME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.41%, which is quite good.
Measured over the past years, CME shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.57% on average per year.
Looking at the last year, CME shows a quite strong growth in Revenue. The Revenue has grown by 10.03% in the last year.
Measured over the past years, CME shows a quite strong growth in Revenue. The Revenue has been growing by 13.14% on average per year.
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
3.2 Future
The Earnings Per Share is expected to grow by 7.48% on average over the next years.
Based on estimates for the next years, CME will show a small growth in Revenue. The Revenue will grow by 5.21% on average per year.
EPS Next Y9.39%
EPS Next 2Y6.87%
EPS Next 3Y6.76%
EPS Next 5Y7.48%
Revenue Next Year5.91%
Revenue Next 2Y5.35%
Revenue Next 3Y5.46%
Revenue Next 5Y5.21%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CME is valuated quite expensively with a Price/Earnings ratio of 25.19.
67.09% of the companies in the same industry are cheaper than CME, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.65, CME is valued at the same level.
CME is valuated rather expensively with a Price/Forward Earnings ratio of 23.56.
63.71% of the companies in the same industry are cheaper than CME, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 34.45. CME is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.19 | ||
| Fwd PE | 23.56 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CME is valued cheaply inside the industry as 87.34% of the companies are valued more expensively.
CME's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.36 | ||
| EV/EBITDA | 10.66 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CME has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.68
PEG (5Y)2.94
EPS Next 2Y6.87%
EPS Next 3Y6.76%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.82%, CME has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 8.60, CME has a dividend in line with its industry peers.
Compared to the average S&P500 Dividend Yield of 2.41, CME is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.82% |
5.2 History
On average, the dividend of CME grows each year by 16.00%, which is quite nice.
CME has paid a dividend for at least 10 years, which is a reliable track record.
CME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
5.3 Sustainability
CME pays out 104.85% of its income as dividend. This is not a sustainable payout ratio.
The dividend of CME is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP104.85%
EPS Next 2Y6.87%
EPS Next 3Y6.76%
NASDAQ:CME (11/25/2025, 12:38:09 PM)
276.1
+0.42 (+0.15%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)
Earnings (Next)
Inst Owners91.46%
Inst Owner Change0.24%
Ins Owners0.25%
Ins Owner Change2.41%
Market Cap99.50B
Revenue(TTM)11.29B
Net Income(TTM)3.72B
Analysts72.73
Price Target291.52 (5.58%)
Short Float %1.15%
Short Ratio2.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.82% |
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP104.85%
Div Incr Years11
Div Non Decr Years11
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.59%
Min EPS beat(2)0.43%
Max EPS beat(2)0.76%
EPS beat(4)3
Avg EPS beat(4)0.49%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)0.72%
EPS beat(12)10
Avg EPS beat(12)0.95%
EPS beat(16)14
Avg EPS beat(16)1.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-1.11%
Max Revenue beat(2)-0.54%
Revenue beat(4)0
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.54%
Revenue beat(8)0
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)7.34%
Revenue beat(16)7
Avg Revenue beat(16)10.88%
PT rev (1m)-0.23%
PT rev (3m)-0.07%
EPS NQ rev (1m)0.03%
EPS NQ rev (3m)-1.26%
EPS NY rev (1m)0.31%
EPS NY rev (3m)-0.51%
Revenue NQ rev (1m)0.31%
Revenue NQ rev (3m)-0.68%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.19 | ||
| Fwd PE | 23.56 | ||
| P/S | 8.81 | ||
| P/FCF | 24.36 | ||
| P/OCF | 23.91 | ||
| P/B | 3.53 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.66 |
EPS(TTM)10.96
EY3.97%
EPS(NY)11.72
Fwd EY4.24%
FCF(TTM)11.33
FCFY4.1%
OCF(TTM)11.55
OCFY4.18%
SpS31.34
BVpS78.22
TBVpS-6.01
PEG (NY)2.68
PEG (5Y)2.94
Graham Number138.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROCE | 24.11% | ||
| ROIC | 18.72% | ||
| ROICexc | 20.09% | ||
| ROICexgc | 151.85% | ||
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A | ||
| FCFM | 36.16% |
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
ROICexc(3y)17.24%
ROICexc(5y)12.98%
ROICexgc(3y)263.94%
ROICexgc(5y)202.43%
ROCE(3y)20.37%
ROCE(5y)15.39%
ROICexgc growth 3Y53.64%
ROICexgc growth 5Y25.03%
ROICexc growth 3Y41.34%
ROICexc growth 5Y22.06%
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.84 | ||
| Debt/EBITDA | 0.36 | ||
| Cap/Depr | 23.26% | ||
| Cap/Sales | 0.68% | ||
| Interest Coverage | 66.76 | ||
| Cash Conversion | 44.34% | ||
| Profit Quality | 109.88% | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | N/A |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)29.97%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.86%
Profit Quality(3y)106.99%
Profit Quality(5y)105.5%
High Growth Momentum
Growth
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
EPS Next Y9.39%
EPS Next 2Y6.87%
EPS Next 3Y6.76%
EPS Next 5Y7.48%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
Revenue Next Year5.91%
Revenue Next 2Y5.35%
Revenue Next 3Y5.46%
Revenue Next 5Y5.21%
EBIT growth 1Y12.23%
EBIT growth 3Y39.48%
EBIT growth 5Y19.95%
EBIT Next Year11.98%
EBIT Next 3Y8.14%
EBIT Next 5Y7.73%
FCF growth 1Y23.34%
FCF growth 3Y16.49%
FCF growth 5Y8.18%
OCF growth 1Y22.71%
OCF growth 3Y15.38%
OCF growth 5Y6.67%
CME GROUP INC / CME FAQ
What is the ChartMill fundamental rating of CME GROUP INC (CME) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CME.
What is the valuation status for CME stock?
ChartMill assigns a valuation rating of 3 / 10 to CME GROUP INC (CME). This can be considered as Overvalued.
Can you provide the profitability details for CME GROUP INC?
CME GROUP INC (CME) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for CME stock?
The Price/Earnings (PE) ratio for CME GROUP INC (CME) is 25.19 and the Price/Book (PB) ratio is 3.53.
How sustainable is the dividend of CME GROUP INC (CME) stock?
The dividend rating of CME GROUP INC (CME) is 4 / 10 and the dividend payout ratio is 104.85%.